UnitedHealth Group Incorporated $UNH Shares Sold by Brooklands Fund Management Ltd

Key Points

• Brooklands Fund Management cut its UnitedHealth stake by 40.6% in the third quarter, selling 7,398 shares and retaining 10,820 shares valued at approximately $3.97 million. Institutional investors collectively own 87.86% of the company.
• UnitedHealth exceeded quarterly expectations with earnings of $4.69 per share versus the $4.14 consensus and revenue of $112.7 billion, while maintaining fiscal 2026 guidance of about $20.50 EPS.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $463.93, though elevated medical costs and uncertainty around commercial and Medicaid margins continue to pose risks.

Brooklands Fund Management Ltd reduced its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 40.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,820 shares of the healthcare conglomerate's stock after selling 7,398 shares during the period. Brooklands Fund Management Ltd's holdings in UnitedHealth Group were worth $3,972,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. General Partner Inc. acquired a new stake in UnitedHealth Group in the third quarter valued at $512,000. PBCay One RSC Ltd acquired a new position in UnitedHealth Group in the first quarter valued at $14,343,000. Lee Johnson Capital Management LLC acquired a new position in UnitedHealth Group in the second quarter valued at $6,180,000. Kinsale Capital Group Inc. grew its holdings in shares of UnitedHealth Group by 13.4% during the second quarter. Kinsale Capital Group Inc. now owns 38,510 shares of the healthcare conglomerate's stock worth $16,006,000 after purchasing an additional 4,557 shares during the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its position in shares of UnitedHealth Group by 1,287.2% during the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 60,022 shares of the healthcare conglomerate's stock worth $16,241,000 after purchasing an additional 55,695 shares in the last quarter. Hedge funds and other institutional investors own 87.86% of the company's stock.

Insider Activity at UnitedHealth Group

In related news, CEO Patrick Conway sold 1,169 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $390.00, for a total value of $455,910.00. Following the transaction, the chief executive officer directly owned 15,328 shares of the company's stock, valued at approximately $5,977,920. This trade represents a 7.09% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.19% of the stock is currently owned by insiders.

Key Headlines Impacting UnitedHealth Group

Here are the key news stories impacting UnitedHealth Group this week:

• Positive Sentiment: Morgan Stanley raised its price target for UnitedHealth Group to $531 from $529, citing signs that Medicare margins are returning to a more favorable range. Morgan Stanley raises UnitedHealth Group price target
• Positive Sentiment: The company’s recent quarterly results exceeded expectations, with earnings and revenue above consensus estimates, while management raised its outlook. Analysts also lifted their longer-term Zacks Research estimates, including FY2027 EPS to $23.29 from $22.28 and FY2028 EPS to $26.60 from $25.74. UnitedHealth raises guidance after quarterly beat
• Neutral Sentiment: Zacks Research maintained a “Hold” rating and issued mixed estimate revisions: some 2027 and 2028 quarterly forecasts increased, while estimates for Q1 2027, Q1 2028, and Q2 2028 were reduced. Its FY2026 EPS estimate of $20.54 is broadly in line with the $20.62 consensus.
• Negative Sentiment: Medical costs remain elevated, creating uncertainty for commercial plans and Medicaid. Investors are also watching whether increased artificial-intelligence spending can generate sufficient savings. The margin recovery in Medicare must broaden across the business to support further upside. UnitedHealth margins recover while medical costs remain high

UnitedHealth Group Price Performance

UnitedHealth Group stock opened at $410.05 on Friday. The stock has a market capitalization of $368.06 billion, a P/E ratio of 19.95, a P/E/G ratio of 1.47 and a beta of 0.60. UnitedHealth Group Incorporated has a 12-month low of $255.96 and a 12-month high of $461.62. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.74 and a quick ratio of 0.78. The firm's 50-day moving average is $389.76 and its two-hundred day moving average is $362.07.

UnitedHealth Group (NYSE:UNH - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The healthcare conglomerate reported $4.69 earnings per share for the quarter, beating analysts' consensus estimates of $4.14 by $0.55. The business had revenue of $112.70 billion during the quarter, compared to analyst estimates of $111.31 billion. UnitedHealth Group had a net margin of 3.53% and a return on equity of 17.95%. The company's revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.59 earnings per share. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Equities analysts predict that UnitedHealth Group Incorporated will post 20.61 earnings per share for the current year.

UnitedHealth Group Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 22nd. Investors of record on Monday, September 14th were issued a $2.32 dividend. This represents a $9.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Monday, September 14th. UnitedHealth Group's payout ratio is presently 53.00%.

Analysts Set New Price Targets

A number of analysts recently issued reports on UNH shares. Barclays decreased their target price on UnitedHealth Group from $441.00 to $440.00 and set an "overweight" rating for the company in a research report on Wednesday, October 14th. Zacks Research downgraded shares of UnitedHealth Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 14th. Cantor Fitzgerald raised their target price on UnitedHealth Group from $440.00 to $495.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Oppenheimer boosted their price target on UnitedHealth Group from $420.00 to $500.00 and gave the stock an "outperform" rating in a research note on Friday, July 17th. Finally, Truist Financial increased their price objective on shares of UnitedHealth Group from $440.00 to $480.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Twenty analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $463.93.

About UnitedHealth Group

UnitedHealth Group Incorporated NYSE: UNH is a diversified health care company that provides health insurance coverage, health care services, pharmacy services and health technology. Its businesses serve individuals, employers, government programs, health care providers and other organizations, primarily in the United States.

The company operates through two principal businesses. UnitedHealthcare offers health benefit plans and related services for employers, individuals, families and government-sponsored programs, including Medicare and Medicaid.

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.